Caladrius Biosciences

Leading development and manufacturing partner to the cell therapy industry. Learn more

Launch date

1980

Employees

11-50 people

Market cap

Enterprise valuation

River Falls Wisconsin (HQ)

http://caladrius.com

https://twitter.com/caladriusbio https://www.facebook.com/CaladriusBio https://www.linkedin.com/company/caladriusbio/

Date	Investors	Amount	Round
-	Small Business Innovation Research (SBIR)	N/A	-
Jan 2000	N/A	N/A	IPO
Apr 2009	RimAsia Capital Partners	$11.0m	Post IPO Equity
May 2014	N/A	$38.0m	Post IPO Equity
Sep 2016	N/A	$12.6m	Late VC
Oct 2017	National Institutes of Health National Heart, Lung, and Blood Institute	$1.9m	Grant
Apr 2020	N/A	$5.0m	Post IPO Equity
Jan 2021	N/A	$25.0m	Post IPO Equity
Mar 2022*	N/A	$2.3m	Post IPO Debt
Apr 2022*	Cend Therapeutics	N/A	Merger
Total Funding		€13.2m

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.

Tech stackLearn more about the technologies and tools that this company uses.

Caladrius Biosciences

Caladrius Biosciences

Recent News about Caladrius Biosciences

Tech stack